

| | | |
|--|---|--|
| Proposal for Task Force Consideration at the ISSC 2015 Biennial Meeting | | <input checked="" type="checkbox"/> Growing Area <input type="checkbox"/> Harvesting/Handling/Distribution <input type="checkbox"/> Administrative |
| Submitter | David C. Deardorff / Elena Dominguez | |
| Affiliation | Abraxis LLC / Zeu-Inmunotec S.L. | |
| Address Line 1 | 54 Steamwhistle Drive / Poligono Plaza, C/ Bari 25 | |
| Address Line 2 | | |
| City, State, Zip | Warminster, PA 18974 USA / 50197 Zaragoza, Spain | |
| Phone | 215-357-3911 / 011-34-976-731-533 | |
| Fax | 215-357-5232 / 011-34-976-524-078 | |
| Email | ddeardorff@abraxiskits.com/edominguez@zeulab.com | |
| Proposal Subject | DSP PPIA Kit for Determination of Okadaic Acid Toxins Group (OA, DTX1, DTX2) in Molluscan Shellfish | |
| Specific NSSP Guide Reference | Section IV. Guidance Documents Chapter II. Growing Areas .11 Approved NSSP Laboratory Tests: Marine Biotoxin Testing | |
| Text of Proposal/ Requested Action | The DSP PPIA kit be approved as a Marine Biotoxin Laboratory Test Method. | |
| Public Health Significance | <p>Okadaic acid (OA) and its analogues, DTX1, DTX2, together with their ester forms are known as the group of OA-toxins. These toxins, lipophilic and heat stable, are produced by dinoflagellates and can be found in various species of shellfish, mainly in filter feeding bivalve molluscs. The OA-toxins group causes Diarrheic Shellfish Poisoning (DSP), which is characterized by symptoms such as diarrhea, nausea, vomiting and abdominal pain. These symptoms may occur in humans shortly after consumption of contaminated bivalve molluscs such as mussels, clams, scallops or oysters. Inhibition of serine/threonine phosphoprotein phosphatases is assumed to be responsible for these toxic effects.</p> <p>Recently in the Pacific Northwest harvest areas, outbreaks of DSP have occurred.</p> | |
| Cost Information | Refer to Para D.1. of the Checklist | |
| Action by 2013 Laboratory Methods Review and Quality Assurance Committee | Recommended referral of Proposal 13-111 to an appropriate committee as determined by the Conference Chairman and directed the Executive Office send a letter to the submitter requesting additional information as provided by the Laboratory Methods Review and Quality Assurance Committee. | |
| Action by 2013 Task Force I | Recommended adoption of Laboratory Methods Review and Quality Assurance Committee recommendation on Proposal 13-111. | |
| Action by 2013 General Assembly | Adopted recommendation of 2013 Task Force I on Proposal 13-111. | |
| Action by FDA May 5, 2014 | Concurred with Conference action on Proposal 13-111. | |